308 related articles for article (PubMed ID: 23808405)
21. Identification and properties of plasma membrane azole efflux pumps from the pathogenic fungi Cryptococcus gattii and Cryptococcus neoformans.
Basso LR; Gast CE; Bruzual I; Wong B
J Antimicrob Chemother; 2015 May; 70(5):1396-407. PubMed ID: 25630649
[TBL] [Abstract][Full Text] [Related]
22. Fluconazole susceptibility testing of Candida species by flow cytometry.
Joung YH; Kim HR; Lee MK; Park AJ
J Infect; 2007 May; 54(5):504-8. PubMed ID: 17084902
[TBL] [Abstract][Full Text] [Related]
23. [Determination of the minimum inhibitory concentration of fluconazole against Cryptococcus neoformans].
Fernández Andreu CM; Pimentel Turino T; Martínez Machín G; González Miranda M
Rev Cubana Med Trop; 1999; 51(1):55-7. PubMed ID: 10887558
[TBL] [Abstract][Full Text] [Related]
24. Correlation of Etest and Neo-Sensitabs diffusion assays on Mueller-Hinton-methylene blue agar with broth microdilution reference method (CLSI-M27-A2) for testing susceptibilities of Cryptococcus neoformans to amphotericin B and fluconazole.
Ochiuzzi ME; Santiso GM; Arechavala AI
Med Mycol; 2010 Sep; 48(6):893-6. PubMed ID: 20370370
[TBL] [Abstract][Full Text] [Related]
25. [First description of phenotypic profile and in vitro drug susceptibility of Cryptococcus spp yeast isolated from HIV-positive and HIV-negative patients in State of Mato Grosso].
Favalessa OC; Ribeiro LC; Tadano T; Fontes CJ; Dias FB; Coelho BP; Hahn RC
Rev Soc Bras Med Trop; 2009; 42(6):661-5. PubMed ID: 20209351
[TBL] [Abstract][Full Text] [Related]
26. Hydroxyaldimines as potent in vitro anticryptococcal agents.
Magalhães TF; da Silva CM; de Fátima Â; da Silva DL; Modolo LV; Martins CV; Alves RB; Ruiz AL; Longato GB; de Carvalho JE; de Resende-Stoianoff MA
Lett Appl Microbiol; 2013 Aug; 57(2):137-43. PubMed ID: 23594040
[TBL] [Abstract][Full Text] [Related]
27. In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans.
Pfaller MA; Messer SA; Hollis RJ; Jones RN
Antimicrob Agents Chemother; 2001 Oct; 45(10):2862-4. PubMed ID: 11557481
[TBL] [Abstract][Full Text] [Related]
28. Antifungal susceptibility testing using the E test: comparison with the broth macrodilution technique.
Chen SC; O'Donnell ML; Gordon S; Gilbert GL
J Antimicrob Chemother; 1996 Feb; 37(2):265-73. PubMed ID: 8707736
[TBL] [Abstract][Full Text] [Related]
29. Molecular types of Cryptococcus neoformans and Cryptococcus gattii in Western Australia and correlation with antifungal susceptibility.
Lee GA; Arthur I; Merritt A; Leung M
Med Mycol; 2019 Nov; 57(8):1004-1010. PubMed ID: 30649538
[TBL] [Abstract][Full Text] [Related]
30. In vitro susceptibility of Cryptococcus neoformans clinical isolates from Egypt to seven antifungal drugs.
Abdel-Salam HA
Mycoses; 2005 Sep; 48(5):327-32. PubMed ID: 16115103
[TBL] [Abstract][Full Text] [Related]
31. In vitro and in vivo antifungal activities of T-2307, a novel arylamidine, against Cryptococcus gattii: an emerging fungal pathogen.
Nishikawa H; Fukuda Y; Mitsuyama J; Tashiro M; Tanaka A; Takazono T; Saijo T; Yamamoto K; Nakamura S; Imamura Y; Miyazaki T; Kakeya H; Yamamoto Y; Yanagihara K; Mukae H; Kohno S; Izumikawa K
J Antimicrob Chemother; 2017 Jun; 72(6):1709-1713. PubMed ID: 28201509
[TBL] [Abstract][Full Text] [Related]
32. Investigation of fluconazole heteroresistance in clinical and environmental isolates of Cryptococcus neoformans complex and Cryptococcus gattii complex in the state of Amazonas, Brazil.
Moreira IMB; Cortez ACA; de Souza ÉS; Pinheiro SB; de Souza Oliveira JG; Sadahiro A; Cruz KS; Matsuura ABJ; Melhem MSC; Frickmann H; de Souza JVB
Med Mycol; 2022 Mar; 60(3):. PubMed ID: 35084497
[TBL] [Abstract][Full Text] [Related]
33. Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998.
Brandt ME; Pfaller MA; Hajjeh RA; Hamill RJ; Pappas PG; Reingold AL; Rimland D; Warnock DW;
Antimicrob Agents Chemother; 2001 Nov; 45(11):3065-9. PubMed ID: 11600357
[TBL] [Abstract][Full Text] [Related]
34. In vitro antifungal susceptibility of clinical isolates of Cryptococcus neoformans var. neoformans and C. neoformans var. gattii.
De Bedout C; Ordóñez N; Gómez BL; Rodríguez MC; Arango M; Restrepo A; Castañeda E
Rev Iberoam Micol; 1999 Mar; 16(1):36-9. PubMed ID: 18473590
[TBL] [Abstract][Full Text] [Related]
35. Clinical evaluation of a dried commercially prepared microdilution panel for antifungal susceptibility testing of five antifungal agents against Candida spp. and Cryptococcus neoformans.
Pfaller MA; Boyken L; Hollis RJ; Messer SA; Tendolkar S; Diekema DJ
Diagn Microbiol Infect Dis; 2004 Oct; 50(2):113-7. PubMed ID: 15474320
[TBL] [Abstract][Full Text] [Related]
36. Antifungal susceptibilities of Cryptococcus species complex isolates from AIDS and non-AIDS patients in Southeast China.
Li M; Liao Y; Chen M; Pan W; Weng L
Braz J Infect Dis; 2012; 16(2):175-9. PubMed ID: 22552461
[TBL] [Abstract][Full Text] [Related]
37. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004).
Pfaller MA; Messer SA; Boyken L; Rice C; Tendolkar S; Hollis RJ; Doern GV; Diekema DJ
J Clin Microbiol; 2005 May; 43(5):2163-7. PubMed ID: 15872236
[TBL] [Abstract][Full Text] [Related]
38. In vivo development of fluconazole resistance in serial Cryptococcus gattii isolates from a cat.
Sykes JE; Hodge G; Singapuri A; Yang ML; Gelli A; Thompson GR
Med Mycol; 2017 Jun; 55(4):396-401. PubMed ID: 28339594
[TBL] [Abstract][Full Text] [Related]
39. Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans.
Thompson GR; Wiederhold NP; Fothergill AW; Vallor AC; Wickes BL; Patterson TF
Antimicrob Agents Chemother; 2009 Jan; 53(1):309-11. PubMed ID: 18955539
[TBL] [Abstract][Full Text] [Related]
40. Cryptococcus neoformans/Cryptococcus gattii species complex melanized by epinephrine: Increased yeast survival after amphotericin B exposure.
Brilhante RSN; Rocha MGD; Oliveira JS; Pereira-Neto WA; Guedes GMM; Cordeiro RA; Sidrim JJC; Rocha MFG; Castelo-Branco DSCM
Microb Pathog; 2020 Jun; 143():104123. PubMed ID: 32169493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
